ADMA Biologics Appoints New Chief Medical Officer
Ticker: ADMA · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $460,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, leadership, cmo
TL;DR
ADMA Biologics just hired a new CMO, Maria T. Palombini, from BioCryst.
AI Summary
On April 1, 2024, ADMA Biologics, Inc. announced the appointment of Maria T. Palombini, M.D., as Chief Medical Officer. Dr. Palombini brings extensive experience in clinical development and medical affairs, most recently serving as Senior Vice President of Medical Affairs at BioCryst Pharmaceuticals.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's strategic direction in clinical development and regulatory affairs.
Risk Assessment
Risk Level: medium — Leadership changes, especially for critical roles like CMO, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- ADMA Biologics, Inc. (company) — Registrant
- Maria T. Palombini, M.D. (person) — Newly appointed Chief Medical Officer
- BioCryst Pharmaceuticals (company) — Dr. Palombini's former employer
- April 1, 2024 (date) — Effective date of appointment
FAQ
What is the effective date of Dr. Palombini's appointment as Chief Medical Officer?
Dr. Maria T. Palombini's appointment as Chief Medical Officer was effective April 1, 2024.
What was Dr. Palombini's most recent role prior to joining ADMA Biologics?
Prior to joining ADMA Biologics, Dr. Palombini served as Senior Vice President of Medical Affairs at BioCryst Pharmaceuticals.
What is ADMA Biologics, Inc.'s primary business?
ADMA Biologics, Inc. is in the business of Biological Products (No Diagnostic Substances).
In which state is ADMA Biologics, Inc. incorporated?
ADMA Biologics, Inc. is incorporated in Delaware.
What is the principal executive office address for ADMA Biologics, Inc.?
The principal executive offices are located at 465 State Route 17, Ramsey, New Jersey 07446.
Filing Stats: 1,722 words · 7 min read · ~6 pages · Grade level 12.2 · Accepted 2024-04-02 17:16:12
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ADMA Nasdaq Global Market
- $460,000 — erg is (i) entitled to a base salary of $460,000 annually, (ii) eligible for an annual c
Filing Documents
- ef20025617_8k.htm (8-K) — 34KB
- ef20025617_ex10-1.htm (EX-10.1) — 99KB
- 0001140361-24-017331.txt ( ) — 292KB
- adma-20240401.xsd (EX-101.SCH) — 4KB
- adma-20240401_lab.xml (EX-101.LAB) — 21KB
- adma-20240401_pre.xml (EX-101.PRE) — 16KB
- ef20025617_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Promotion of Kaitlin Kestenberg to Chief Operating Officer and SVP, Compliance Effective April 1, 2024 (the "Effective Date"), Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc. (the "Company"), was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company (the "Promotion"). Ms. Kestenberg, age 37, joined the Company as Clinical Research Manager in 2011 and has received multiple promotions and positions of increasing responsibility. Ms. Kestenberg served as the Company's Senior Vice President, Compliance & Project Operations from April 2023 through March 2024, as Vice President, Compliance & Project Management and Acting Head of Analytical and Process Development from May 2021 through March 2023, as Vice President, Compliance & Project Management from April 2019 until May 2021 and as Senior Director, Compliance, Project Management & Clinical Operations from January 2018 through March 2019. Prior to joining the Company, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics, Inc. and Merck & Co. Inc. Ms. Kestenberg holds a B.A. from the State University of New York at Albany and an M.S.J. from Seton Hall University. There have been no related party transactions between the Company and Ms. Kestenberg reportable under Item 404(a) of Regulation S-K, there are no arrangements or understandings between Ms. Kestenberg and any other person pursuant to which she was appointed as an officer reportable under Item 404(b) of Regulation S-K, and Ms. Kestenberg has no family relationships with any of our directors or executive officers reportable under Item 401(d) of Regulation S-K. On the Effective Date, the Company and Ms. Kestenberg entered into an Employment Agree
01
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 10.1 Employment Agreement, dated April 1, 2024, by and between the Company and Kaitlin Kestenberg. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. April 2, 2024 ADMA Biologics, Inc. By: /s/ Adam S. Grossman Name: Adam S. Grossman Title: President, Chief Executive Officer and Interim Chief Financial Officer